Cooper Companies Inc (COO) Stock AnalysisCOOStock AnalysisCooper Companies Inc

The Cooper Companies, Inc. is a medical device company. The Company's segments include CooperVision and CooperSurgical. The CooperVision segment is engaged in developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics. Its daily disposable silicone hydrogel contact lens products include MyDay daily disposable, MyDay daily disposable toric, MyDay daily disposable multifocal, and MyDay Energys. The CooperSurgical segment provides a portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. Its brands include ALLY II UPS, Advincula Delineator, Apple-Hunt Secondary Cannula, Bakri Postpartum Balloon, California Cryobank, Carter-Thomason, Cell Care, Cells for Life, Coda, Cord Blood Registry, Core Cryolab, Donor Egg Bank USA, ER-Complete, Embryo Options, and Endosee. It operates in the Healthcare sector (OPHTHALMIC GOODS industry).

Currently, Cooper Companies Inc (COO) is not a strong buy. The stock is priced at $71.17, which is below the average analyst price target of $76. This indicates potential upside, but the stock has a low RSI of 20.795, suggesting it is oversold. However, the company has recently reported a significant decline in net income, with a net loss of $77.9 million in Q2 2026, which raises concerns about its financial health. The main risk is the projected sales growth slowing to 4.2% over the next 12 months, which is below the healthcare sector average.

15 analysts cover COO: 10 rate it Buy, 5 Hold and 0 Sell. The average price target is 90.33.